179 related articles for article (PubMed ID: 30621390)
1. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy.
Liu Y; Chen XG; Yang PP; Qiao ZY; Wang H
Biomacromolecules; 2019 Feb; 20(2):882-892. PubMed ID: 30621390
[TBL] [Abstract][Full Text] [Related]
2. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
3. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
4. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
5. Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy.
Su Z; Xiao Z; Huang J; Wang Y; An Y; Xiao H; Peng Y; Pang P; Han S; Zhu K; Shuai X
ACS Appl Mater Interfaces; 2021 Mar; 13(11):12845-12856. PubMed ID: 33709684
[TBL] [Abstract][Full Text] [Related]
6. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
7. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
8. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
[TBL] [Abstract][Full Text] [Related]
9. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
10. MMP-responsive transformation nanomaterials with IAP antagonist to boost immune checkpoint therapy.
Wang T; He Z; Yuan CS; Deng ZW; Li F; Chen XG; Liu Y
J Control Release; 2022 Mar; 343():765-776. PubMed ID: 35181414
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.
Gu Z; Wang Q; Shi Y; Huang Y; Zhang J; Zhang X; Lin G
J Control Release; 2018 Sep; 286():369-380. PubMed ID: 30096401
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
[TBL] [Abstract][Full Text] [Related]
13. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
Du Y; Liang X; Li Y; Sun T; Xue H; Jin Z; Tian J
Cancer Lett; 2018 Feb; 414():230-238. PubMed ID: 29175457
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive charge-conversional and NIR responsive bubble-generating liposomal system for synergetic thermo-chemotherapy.
Chen MM; Song FF; Feng M; Liu Y; Liu YY; Tian J; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2018 Jul; 167():104-114. PubMed ID: 29631221
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
Ou W; Jiang L; Gu Y; Soe ZC; Kim BK; Gautam M; Poudel K; Pham LM; Phung CD; Chang JH; Kim JR; Ku SK; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2019 Oct; 11(40):36333-36346. PubMed ID: 31535550
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug.
Chen K; Cai H; Zhang H; Zhu H; Gu Z; Gong Q; Luo K
Acta Biomater; 2019 Jan; 84():339-355. PubMed ID: 30503561
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.
Gao F; Zhang C; Qiu WX; Dong X; Zheng DW; Wu W; Zhang XZ
Small; 2018 Sep; 14(37):e1802403. PubMed ID: 30129176
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
20. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
